TRU-SENTIMENT · DeltaNeutral
PDSB Trading Analysis - 10/02/2026 03:15 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
PDSB (PDS Biotechnology Corporation Common Stock) at $0.74. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $140 vs put $0. RSI 67.6.
- Symbol
- PDSB
- Price
- $0.74
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- medium
- Published
- 2026-10-02 15:15:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis—Delta 40–60 Options:
Call dollar volume: $140.00 (100.00%)
Put dollar volume: $0.00 (0.00%)
Total directional dollar volume: $140.00
Key Statistics: PDSB
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-0.64 |
| Market cap | $53.59M |
| Shares outstanding | 72.5M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.11 |
| 52-week low | $0.20 |
| 52-week high | $1.55 |
| Historical volatility | 234.6% |
Ownership & trading
| Institutional ownership | 5.3% |
| Average daily volume | 69.0M sh |
Reported figures; no analyst estimates.
📈 Analysis
PDSB Stock Analysis
Data timestamp: October 2, 2026, with the latest completed daily close at $0.72 and the latest supplied intrabar at $0.74.
PDSB remains a highly speculative, loss-making biotech following an extraordinary September price spike. Momentum indicators are mixed: the MACD and longer moving averages remain positive, while the recent pullback, declining short-term price action, and overbought RSI show that volatility and retracement risk remain substantial.
News Headlines & Context:
- Clinical-development context: General company context identifies Praxis Precision Drugs as a clinical-stage biotechnology company whose valuation can be highly sensitive to trial results, regulatory milestones, safety findings, and clinical timelines. No current trial result is included in the supplied data.
- September volatility catalyst: The embedded price history shows a surge from a $0.22 close on September 4 to a $1.06 intraday high on September 16, followed by a retreat to $0.72 by October 1. This indicates that speculative repositioning or event-driven trading may have materially distorted the prior price base.
- Fundamental risk context: Trailing EPS is negative $0.64, no P/E is available, and key financial fields—including revenue, margins, debt, cash flow, and analyst targets—are missing. That absence of reported operating data is itself a major biotech risk.
- Current catalyst gap: The supplied files contain no earnings date, FDA decision date, trial readout date, financing announcement, or partnership update with which to confirm an upcoming catalyst.
News context is separate from the data-driven analysis below. The technical data show a post-spike correction rather than a confirmed fundamental revaluation.
Fundamental Analysis:
| Metric | PDSB Data | Interpretation |
|---|---|---|
| Trailing EPS | -$0.64 | The company is not profitable on a trailing basis. |
| Trailing P/E | Not available | Negative EPS makes a conventional P/E meaningless. |
| Forward P/E | Not available | No forward earnings estimate is supplied. |
| PEG ratio | Not available | No sector or peer PEG comparison can be made from the dataset. |
| Market capitalization | $53.59M | Small capitalization increases liquidity, dilution, and volatility risk. |
| Shares outstanding | 72.47M | Large share count relative to market value is consistent with a highly speculative equity. |
| Dividend yield | 0.00% | No income support is present. |
| Institutional ownership | 5.31% | Relatively limited institutional participation may amplify price moves. |
| Average volume | 69.00M | Elevated turnover reflects the post-spike speculative period, though average volume is not directly comparable with the latest session. |
| Beta | 1.11 | Moderately positive market sensitivity, but PDSB’s company-specific volatility is much higher. |
| Historical volatility | 234.64% | Extreme volatility makes normal valuation and technical signals less reliable. |
Operating Performance
- Revenue growth: Total revenue and YoY growth are not provided, so no revenue trend can be verified.
- Gross, operating, and net margins: All are unavailable. The negative trailing EPS nevertheless confirms that the company is currently loss-making on this measure.
- Debt-to-equity: Not provided; balance-sheet leverage cannot be assessed.
- Return on equity: Not provided.
- Free cash flow: Not provided, preventing an assessment of cash burn and financing dependence.
- Analyst consensus: No analyst recommendation, target price, or opinion count is supplied.
Current Market Position:
The latest completed close of $0.72 was down 2.52% from $0.73 on September 30. The stock declined from a $0.81 close on September 25, while the October 1 session reached a high of $0.76 and a low of $0.70.
On October 2, the latest supplied intrabar recovered to $0.74 from a recent intraday low of $0.73. That rebound improved the final observed price by approximately 1.80% from the recent intraday low, but the stock remained roughly 1.20% below the October 2 opening price of $0.75.
The broader structure remains corrective: PDSB closed approximately 30.09% below its $1.06 30-day high and 27.76% below the September 16 close of $0.99.
Technical Analysis:
Technical Indicators
Interactive charts load with JavaScript. This text is the crawlable summary.